Movement Alert|UnitedHealth Rises 3.04% in Regular Trading, Q2 Earnings Far Exceed Expectations as Multiple Banks Raise Targets

Market Focus07-29 02:57

On July 29, UnitedHealth rose 3.04% in regular trading, trading at $430.22/share, with turnover of $1.271 billion. The stock continued its upward momentum following a blowout Q2 earnings report and a wave of analyst target price upgrades.

UnitedHealth reported Q2 adjusted EPS of $6.38, significantly beating the analyst consensus range of $4.86–$4.91, representing a 56% year-over-year increase. Revenue came in at $112.03 billion versus estimates of $110.81 billion. The company raised its full-year adjusted EPS guidance to $19.50–$20.00, well above the prior Street estimate of $18.49, and announced plans for at least $5 billion in share buybacks. Management noted Medicare medical cost growth is trending below the initial ~10% estimate, supporting further margin improvement.

Following the results, multiple investment banks raised their price targets: Morgan Stanley to $529, Bank of America to $512, Piper Sandler to $499, Cantor Fitzgerald to $495, Mizuho to $493, Jefferies to $490, and RBC to $478, reflecting broad confidence in the earnings recovery trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment